BACKGROUND Duloxetine has joined venlafaxine on the antidepressant market as a
second serotonin–norepinephrine reuptake inhibitor. No previous studies have directly …

BACKGROUND: Clinical trials assessing antidepressant therapies typically include separate
assessments of efficacy (benefit) and adverse events (risk). Global benefit–risk (GBR) …

Schueler Y‐B, Koesters M, Wieseler B, Grouven U, Kromp M, Kerekes MF, Kreis J, Kaiser T,
Becker T, Weinmann S. A systematic review of duloxetine and venlafaxine in major …

Background Data comparing duloxetine with existing antidepressant treatments is limited. A
comparison of duloxetine with fluoxetine has been performed but no comparison with …

Duloxetine (Cymbalta®) is an orally administered, selective serotonin and noradrenaline
reuptake inhibitor (SNRI) that has been approved for the treatment of major depressive …

Background Desvenlafaxine and duloxetine are selective serotonin and norepinephrine
reuptake inhibitors. Their efficacy has not been directly compared using statistical …

Background Duloxetine and venlafaxine extended release (venlafaxine XR) are SNRIs
indicated for the treatment of MDD. This study addresses whether duloxetine and …

Background: Major depressive disorder (MDD) is a common, chronic illness associated with
substantial disability and economic burden. Although a number of effective antidepressants …

Introduction: Desvenlafaxine, the active metabolite of venlafaxine, is a serotonin
norepinephrine reuptake inhibitor (SNRI) recently approved for the treatment of major …

Specific serotonin reuptake inhibitors (SSRIs) are considered as first-line treatment in major
depressive disorder (MDD). There is evidence that venlafaxine may be more effective than …